Answers are grounded in this paper and cite their sources.
Human pluripotent stem cells represent a unique reservoir that could be utilized for generating cells of a given lineage.Cancer immunotherapy field could benefit from this, since one of the key limitations in developing an effective immune based cancer therapy is the lack of sufficient high avidity anti-tumor T cells in a great majority of cancer patients.The main reason for this is the fact that most human tumor antigens are "self-antigens" and most self reactive high avidity T cells are deleted during development to avoid autoimmunity.This manuscript reviews recent advances towards differentiating human pluripotent stem (hPS) cells into different immune effector cells, and potential strategies to utilize hPS cells in T cell based cancer immunotherapy approaches.We will also discuss the advantages and concerns associated with their clinical applications.
No takes yet. Share an insight, caveat, or question.
Arvind Chhabra (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: